Container selection may seem straightforward, but it is a frequent source of regulatory observations and approval delays in pharmaceutical development. Regulatory agencies expect a risk-based, well-documented approach to container closure system (CCS) selection, especially for stability testing. This article highlights the most common regulatory pitfalls and how to avoid them when selecting containers for your pharmaceutical product.
1. Using a Different Container During Stability Studies Than in Marketed Product
This is one of the most cited issues in FDA and EMA reviews. Stability studies must be performed in the final market-intended packaging configuration. Using interim containers during development without bridging studies can result in invalidated data.
- Incorrect: Conducting stability in Type II glass, while commercial pack is HDPE
- Correct: Conducting stability in the same container type, even during early development
If a change is unavoidable, comparative stability and extractables/leachables (E&L) studies must justify equivalence.
2. Missing or Incomplete Container Closure Integrity (CCI) Data
According to USP , CCI testing is mandatory for sterile products. Many submissions fail to provide this data or rely solely on visual inspection.
- Always perform quantitative CCI testing such as vacuum decay, helium leak, or microbial ingress.
- Include results before and after accelerated stability and shipping simulation.
- Document the methods, acceptance criteria, and
3. Inadequate Extractables and Leachables (E&L) Justification
Missing or generic E&L data is a top reason for regulatory queries. Each container component—vial, stopper, cap—must be evaluated for extractable and leachable substances using validated analytical methods (e.g., LC-MS, GC-MS, ICP-MS).
- Test materials at storage-representative conditions (e.g., 40°C/75% RH)
- Match migration levels with permitted daily exposure (PDE)
- Include worst-case scenarios (e.g., high surface contact, low fill volumes)
4. Lack of Closure System Documentation in CTD
CTD Module 3.2.P.7 requires detailed packaging information. Many dossiers either lack full closure specs or reference outdated vendor files.
Include the following:
- Part numbers, drawings, and material details for each closure
- Validation reports for sealing process and integrity
- Photostability and stress test outcomes
- Change control history and requalification records
Refer to regulatory compliance portals for submission guidance.
5. Choosing Containers Based on Cost or Convenience
Selecting a container based on availability or pricing, rather than compatibility, often leads to compliance issues. Regulators expect evidence that the container does not adversely affect the drug’s quality.
Always conduct compatibility studies covering:
- Assay and impurity profile changes
- pH, color, or odor shifts
- Adsorption of API on the container walls
Document findings in both development reports and regulatory files.
6. Ignoring Environmental and Climatic Zone Compatibility
Packaging performance can vary drastically under different climatic conditions. Regulatory bodies like WHO and CDSCO expect data covering ICH Zones I–IVb if the product is intended for global markets.
- Use high-barrier containers (e.g., Type I glass, PVDC blister) for Zone IVb (hot and humid)
- Simulate shipping and storage in high-stress environments
- Ensure closures don’t lose torque or seal strength under thermal cycling
Failure to account for regional stress can lead to leakage, delamination, and microbial ingress.
7. Non-Validated Sealing Equipment or Inconsistent Process Control
Even with the right container and closure, improper sealing can compromise stability results. Regulatory inspections often uncover inconsistencies in crimping, torque application, or capping processes.
- Use calibrated and qualified sealing equipment
- Validate torque ranges or crimp depths
- Document process control checks in batch records
Consult equipment qualification references for process validation protocols.
8. Failing to Requalify Closures After Vendor Change
Many companies treat a vendor switch as a logistical change. However, regulators view it as a critical quality attribute. Even slight variations in stopper material, coating, or dimensions can affect integrity and leachables.
- Re-evaluate E&L profiles
- Revalidate CCI and sealing process
- Update closure specifications and change control logs
- Perform a bridging stability study if warranted
9. Overlooking Secondary Packaging’s Role in Stability
Some regulatory rejections have stemmed from inadequate secondary packaging. Cartons, trays, and overwraps affect light, moisture, and mechanical protection—especially in long-term storage.
- Ensure secondary packaging protects the container system during transport and storage
- Conduct drop tests, UV aging, and compression studies
- Include labeling adhesion tests under humidity and heat stress
10. Incomplete SOPs and Training for Closure Handling
GMP inspections often identify SOP gaps for closure receipt, inspection, sealing, and documentation. Regulatory concerns increase if operators lack adequate training or if SOPs lack clarity.
Ensure SOPs cover:
- Closure sampling and inspection
- In-process checks for sealing integrity
- Cleaning and storage of closures
- Deviation and corrective action tracking
See SOP training pharma for relevant templates.
Case Study: FDA 483 Issued for Incomplete Container Validation
A US-based manufacturer received a Form 483 observation during a pre-approval inspection because their commercial product was stored in HDPE bottles, while stability batches were placed in glass. No justification or bridging data was provided. The FDA required repeat stability studies and delayed product approval by 9 months. This case underscores the importance of alignment between development and commercial packaging.
Conclusion
Container and closure selection is a high-impact area of regulatory scrutiny in stability studies. From mismatched materials to inadequate documentation, every misstep can trigger data integrity concerns or compliance findings. A proactive, data-driven, and risk-based approach is essential. By avoiding these ten regulatory pitfalls, pharmaceutical companies can protect their product quality, accelerate approvals, and strengthen inspection readiness.
References:
- ICH Q1A(R2): Stability Testing of New Drug Substances and Products
- USP : Container Closure Integrity Testing
- WHO Technical Report Series on Pharmaceutical Packaging
- EMA Guideline on Plastic Immediate Packaging Materials
- FDA Guidance for Industry: Container Closure Systems